232 related articles for article (PubMed ID: 21796767)
1. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.
Orgel E; Jain S; Ji L; Pollick L; Si S; Finlay J; Freyer DR
Pediatr Blood Cancer; 2012 Jun; 58(6):953-8. PubMed ID: 21796767
[TBL] [Abstract][Full Text] [Related]
2. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
3. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
4. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens.
Kolinsky DC; Hayashi SS; Karzon R; Mao J; Hayashi RJ
J Pediatr Hematol Oncol; 2010 Mar; 32(2):119-23. PubMed ID: 20098336
[TBL] [Abstract][Full Text] [Related]
5. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
Knight KR; Kraemer DF; Neuwelt EA
J Clin Oncol; 2005 Dec; 23(34):8588-96. PubMed ID: 16314621
[TBL] [Abstract][Full Text] [Related]
6. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
7. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
Dean JB; Hayashi SS; Albert CM; King AA; Karzon R; Hayashi RJ
J Pediatr Hematol Oncol; 2008 Feb; 30(2):130-4. PubMed ID: 18376265
[TBL] [Abstract][Full Text] [Related]
8. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
9. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
[TBL] [Abstract][Full Text] [Related]
10. Hearing impairment after platinum-based chemotherapy in childhood.
Einar-Jon E; Trausti O; Asgeir H; Christian M; Thomas W; Måns M; Jon K; Hannes P
Pediatr Blood Cancer; 2011 Apr; 56(4):631-7. PubMed ID: 21298751
[TBL] [Abstract][Full Text] [Related]
11. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
Waissbluth S; Del Valle Á; Chuang A; Becker A
Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
[TBL] [Abstract][Full Text] [Related]
12. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.
Neuwelt EA; Gilmer-Knight K; Lacy C; Nicholson HS; Kraemer DF; Doolittle ND; Hornig GW; Muldoon LL
Pediatr Blood Cancer; 2006 Aug; 47(2):174-82. PubMed ID: 16086410
[TBL] [Abstract][Full Text] [Related]
13. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
Kushner BH; Budnick A; Kramer K; Modak S; Cheung NK
Cancer; 2006 Jul; 107(2):417-22. PubMed ID: 16779793
[TBL] [Abstract][Full Text] [Related]
14. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.
Clemens E; de Vries AC; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; Pluijm SF; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; Neggers SJ; van Grotel M; M van den Heuvel-Eibrink M
Pediatr Hematol Oncol; 2017 Mar; 34(2):120-129. PubMed ID: 28590156
[TBL] [Abstract][Full Text] [Related]
15. Platinum-induced hearing loss after treatment for childhood cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
[TBL] [Abstract][Full Text] [Related]
16. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
18. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
Lafay-Cousin L; Purdy E; Huang A; Cushing SL; Papaioannou V; Nettel-Aguirre A; Bouffet E
Pediatr Blood Cancer; 2013 Feb; 60(2):287-92. PubMed ID: 23002030
[TBL] [Abstract][Full Text] [Related]
19. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.
Parsons SK; Neault MW; Lehmann LE; Brennan LL; Eickhoff CE; Kretschmar CS; Diller LR
Bone Marrow Transplant; 1998 Oct; 22(7):669-74. PubMed ID: 9818694
[TBL] [Abstract][Full Text] [Related]
20. Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.
Ilveskoski I; Saarinen UM; Wiklund T; Perkkiö M; Salmi TT; Lanning M; Mäkipernaa A; Pihko H
Med Pediatr Oncol; 1996 Jul; 27(1):26-31. PubMed ID: 8614387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
